WHOCC
Postal address:
WHO Collaborating Centre for Drug Statistics Methodology
Norwegian Institute of Public Health
Postboks 222 Sk°yen
0213 Oslo
Norway

Visiting/delivery address:
Sandakerveien 24C
Bygg C
0473 Oslo
Norway

Tel:  +47 21 07 81 60
E-mail:
 
Copyright/Disclaimer

List of temporary ATC codes decided at the latest meetings of the WHO International Working Group for Drug Statistics Methodology. Comments or objections to the ATC codes should be forwarded to the WHO Collaborating Centre for Drug Statistics Methodology within the deadline. If no objections are received, the new ATC codes will be considered final and included in the ATC/DDD Index. The year of implementation in the ATC/DDD Index is given in the list.

ATC codeATC level name (INN/generic name)Deadline for objection to temporary code Implementation in the ATC/DDD index
A02BC09tegoprazan01.02.20212022
A05AX04maralixibat chloride01.02.20212022
A05AX05odevixibat01.02.20212022
A08AA12setmelanotide01.02.20212022
A10BD27metformin, linagliptin and empagliflozin01.02.20212022
A10BX15imeglimin01.02.20212022
A16AB20pegunigalsidase alfa01.02.20212022
A16AX19fosdenopterin01.02.20212022
A16AX20lonafarnib01.02.20212022
B03XA07daprodustat01.02.20212022
B03XA08vadadustat01.02.20212022
B06AC06berotralstat01.02.20212022
B06AX03voxelotor01.02.20212022
C08CA17levamlodipine01.02.20212022
C10AX17evinacumab01.02.20212022
C10AX18volanesorsen01.02.20212022
C10BA11pravastatin and ezetimibe01.02.20212022
D03AX15trafermin01.02.20212022
D10AX06clascoterone01.02.20212022
D11AH08abrocitinib01.02.20212022
J01RA14norfloxacin and metronidazole01.02.20212022
J01RA15cefixime and ornidazole01.02.20212022
J02AC06oteseconazole01.02.20212022
J05AB16remdesivir01.02.20212022
J07AG54haemophilus influenza B, combinations with meningococcus C,Y, conjugated01.02.20212022
J07BX03covid-19 vaccines01.02.20212022
L01EA06asciminib01.02.20212022
L01EX22selpercatinib01.02.20212022
L01EX23pralsetinib01.02.20212022
L01XC42prolgolimab01.02.20212022
L01XK06pamiparib01.02.20212022
L01XX72tazemetostat01.02.20212022
L01XX73sotorasib01.02.20212022
L04AA48belumosudil01.02.20212022
L04AA49peficitinib01.02.20212022
L04AA50ponesimod01.02.20212022
L04AA51anifrolumab01.02.20212022
L04AA52ofatumumab01.02.20212022
L04AA53teprotumumab01.02.20212022
L04AC20netakimab01.02.20212022
L04AC21bimekizumab01.02.20212022
L04AX09diroximel fumarate01.02.20212022
M05BX07vosoritide01.02.20212022
M09AX12viltolarsen01.02.20212022
N02AX51tilidine and naloxone01.02.20212022
N02BG12tanezumab01.02.20212022
N02CC08lasmiditan01.02.20212022
N02CD04ubrogepant01.02.20212022
N02CD05eptinezumab01.02.20212022
N02CD06rimegepant01.02.20212022
N05AD10lumateperone01.02.20212022
N05CM21lemborexant01.02.20212022
N06DX03aducanumab01.02.20212022
N07XX16deutetrabenazine01.02.20212022
P01AA30tilbroquinol and tiliquinol01.02.20212022
P01AB52metronidazole and diloxanide01.02.20212022
P01BB52chloroquine and proguanil01.02.20212022
P01BF07artemisinin and piperaquine01.02.20212022
P01BF08 artemisinin and naphthoquine01.02.20212022
P01BF09artesunate, sulfadoxine and pyrimethamine01.02.20212022
P03AX07abametapir01.02.20212022
R03DX11tezepelumab01.02.20212022
S01EX07ripasudil01.02.20212022
S01GX12cetirizine01.02.20212022
S01LA08bevacizumab01.02.20212022
V03AF12trilaciclib01.02.20212022
V03AG05 sodium phosphate 01.02.20212022
V09GX05ammonia (13N)01.02.20212022
V09IX14gallium (68Ga) PSMA-1101.02.20212022

Last updated: 2020-11-25